drug comparison charts

Compare specialty medications side by side — route, frequency, and key differences. Useful when your insurer requires switching to a biosimilar or alternative.

Immunoglobulin

IVIG & SCIG Products Comparison

Clinical comparison of all FDA-approved immunoglobulin products for providers. Compare concentration, IgA content, stabilizer, sugar content, osmolality, storage, FDA-approved indications, and compatibility considerations. Sources: FDA prescribing information.

16 drugs compared

Biosimilars

Stelara Biosimilars Comparison

Compare Stelara (ustekinumab) biosimilars to the reference product. Stelara biosimilars offer the same efficacy for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis at potentially lower cost. Multiple biosimilars are now FDA-approved.

7 drugs compared

Humira Biosimilars Comparison

Compare adalimumab biosimilars to brand Humira. Multiple biosimilars are now available, and most insurers require them before brand Humira. Products differ primarily in citrate content (injection pain), device design, and copay programs.

6 drugs compared

Eylea Biosimilars Comparison

Compare aflibercept biosimilars to brand Eylea for wet AMD and DME. Several biosimilars have been FDA-approved, offering potential cost savings for retinal anti-VEGF therapy.

4 drugs compared

Rituximab Biosimilars Comparison

Compare rituximab biosimilars to brand Rituxan. Rituximab is used for NHL, CLL, RA, and off-label for many autoimmune conditions. Biosimilars offer significant cost savings for this widely used infusion therapy.

4 drugs compared

Neurology

MS Biologics Comparison

Compare disease-modifying therapies (DMTs) for multiple sclerosis. Options range from platform therapies to high-efficacy B-cell depleting agents. Choice depends on disease activity, safety profile, route preference, and insurance coverage.

9 drugs compared

CGRP Migraine Drugs Comparison

Compare CGRP pathway therapies for migraine prevention and acute treatment. These targeted therapies block calcitonin gene-related peptide (CGRP), a key molecule in migraine. Options include monthly injections, quarterly infusions, and oral medications.

8 drugs compared

Rheumatology

RA Biologics Comparison

Compare biologic and targeted synthetic DMARDs for rheumatoid arthritis. After failing conventional DMARDs, patients have multiple biologic options. Choice depends on mechanism, route, insurance coverage, and individual risk factors.

8 drugs compared

Dermatology

Psoriasis Biologics Comparison

Compare biologic therapies for moderate-to-severe plaque psoriasis. Modern IL-17 and IL-23 inhibitors offer high skin clearance rates. Choice depends on insurance formulary position, mechanism preference, and dosing convenience.

8 drugs compared

Gastroenterology

Crohn's Disease Biologics Comparison

Compare biologic and targeted therapies for moderate-to-severe Crohn's disease. TNF inhibitors were the first biologics for Crohn's; newer options include IL-23 inhibitors, integrin inhibitors, and JAK inhibitors.

8 drugs compared

Endocrinology

GLP-1 Drugs Comparison

Compare GLP-1 receptor agonists for type 2 diabetes and weight management. These drugs have become some of the most prescribed (and most denied) medications in the U.S. Coverage varies dramatically between diabetes and weight loss indications.

5 drugs compared

Transplant

Transplant Rejection Drugs Comparison

Compare immunosuppressive medications used to prevent organ transplant rejection. These drugs are critical for maintaining transplant function and must be taken consistently for life. Formulary switches and generic substitution can be particularly risky in this category.

6 drugs compared